109 related articles for article (PubMed ID: 7603305)
1. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo.
Hoyo-Vadillo C; Mandema JW; Danhof M
Life Sci; 1995; 57(4):325-33. PubMed ID: 7603305
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.
Tuk B; van Gool T; Danhof M
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):235-50. PubMed ID: 12449497
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.
Mandema JW; Tukker E; Danhof M
Br J Pharmacol; 1991 Mar; 102(3):663-8. PubMed ID: 1364836
[TBL] [Abstract][Full Text] [Related]
4. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Mandema JW; Tukker E; Danhof M
J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats.
Hovinga S; Stijnen AM; Langemeijer MW; Mandema JW; van Bezooijen CF; Danhof M
Br J Pharmacol; 1992 Sep; 107(1):171-7. PubMed ID: 1422570
[TBL] [Abstract][Full Text] [Related]
6. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.
Mandema JW; Kuck MT; Danhof M
J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Jonker DM; Vermeij DA; Edelbroek PM; Voskuyl RA; Piotrovsky VK; Danhof M
Epilepsia; 2003 Mar; 44(3):329-38. PubMed ID: 12614388
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling.
Breimer LT; Hennis PJ; Burm AG; Danhof M; Bovill JG; Spierdijk J; Vletter AA
Clin Pharmacokinet; 1990 Mar; 18(3):245-53. PubMed ID: 2323155
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis.
Breimer LT; Burm AG; Danhof M; Hennis PJ; Vletter AA; de Voogt JW; Spierdijk J; Bovill JG
Clin Pharmacokinet; 1991 Jun; 20(6):497-508. PubMed ID: 2044333
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats.
Visser SA; Huntjens DR; van der Graaf PH; Peletier LA; Danhof M
J Pharmacol Exp Ther; 2003 Nov; 307(2):765-75. PubMed ID: 12975494
[TBL] [Abstract][Full Text] [Related]
11. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.
Cleton A; Mazee D; Voskuyl RA; Danhof M
Br J Pharmacol; 1999 May; 127(1):227-35. PubMed ID: 10369477
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.
Mandema JW; Tuk B; van Steveninck AL; Breimer DD; Cohen AF; Danhof M
Clin Pharmacol Ther; 1992 Jun; 51(6):715-28. PubMed ID: 1611810
[TBL] [Abstract][Full Text] [Related]
13. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.
Aarons L; Mandema JW; Danhof M
J Pharmacokinet Biopharm; 1991 Oct; 19(5):485-96. PubMed ID: 1783988
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.
Cox EH; Van Hemert JG; Tukker EJ; Danhof M
J Pharmacol Toxicol Methods; 1997 Oct; 38(2):99-108. PubMed ID: 9403781
[TBL] [Abstract][Full Text] [Related]
15. Quantification of pharmacodynamic interactions between dexmedetomidine and midazolam in the rat.
Bol CJ; Vogelaar JP; Tang JP; Mandema JW
J Pharmacol Exp Ther; 2000 Jul; 294(1):347-55. PubMed ID: 10871332
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.
Greenblatt DJ; Ehrenberg BL; Culm KE; Scavone JM; Corbett KE; Friedman HL; Harmatz JS; Shader RI
J Clin Pharmacol; 2004 Jun; 44(6):605-11. PubMed ID: 15145968
[TBL] [Abstract][Full Text] [Related]
17. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers.
Hardmeier M; Zimmermann R; Rüegg S; Pflüger M; Deuster S; Suter K; Donzelli M; Drewe J; Krähenbühl S; Fuhr P; Haschke M
Clin Pharmacol Ther; 2012 May; 91(5):856-62. PubMed ID: 22453191
[TBL] [Abstract][Full Text] [Related]
18. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
19. Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy.
Cleton A; Voskuyl RA; Danhof M
Br J Pharmacol; 1998 Oct; 125(4):615-20. PubMed ID: 9831893
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.
Tuk B; van Oostenbruggen MF; Herben VM; Mandema JW; Danhof M
J Pharmacol Exp Ther; 1999 May; 289(2):1067-74. PubMed ID: 10215689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
